SmallCapReview.com has been a leading site for information on small cap stocks and penny stocks since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Dynavax Technologies Corporation (Nasdaq: DVAX) Trading at $1.67, Up $0.18. Today announced data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist (1) is well tolerated and safe and (2) induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
What They Do: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines.
To read more about Dynavax visit http://www.smallcapreview.com/dvax.htm
Achillion Pharmaceuticals (Nasdaq: ACHN) Trading at $2.42, Up $0.13. Announced yesterday after market close that Michael D. Kishbauch, Achillion's President and Chief Executive Officer, will lead the Company's management team in hosting a Corporate and Clinical Update conference call on Monday, February 1, 2010 at 4:30 p.m. Eastern time.
Management will bring investors up to date on the Company's progress and plans in its three distinct HCV programs:
Protease inhibitor program featuring ACH-1625, a compound that has recently completed successful proof-of-concept Phase Ib testing, and has demonstrated high potency, unique pharmacokinetic properties and an excellent safety profile;
Novel mechanism NS4A antagonist program featuring ACH-1095, a compound shown be a potent inhibitor of HCV replication and which is preparing to enter Phase I clinical studies pending FDA consultation; and Resistance-focused HCV program featuring compounds which, in pre-clinical studies have been shown to be several orders of magnitude more potent than other direct-acting inhibitors currently under development, and which may be effective in prevention and treatment of emerging resistant variants.
In addition, the Company will provide an update on partnering efforts related to its non-HCV assets, elvucitabine and ACH-702.
What They Do: Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HCV, HIV and resistant bacterial infections.
To read more about Achillion visit http://www.smallcapreview.com/achn.htm.
TheStreet.com, Inc. (Nasdaq: TSCM) Trading at $3.22, Up $0.70. Announced yesterday after rmarket close financial results for the second and third quarters of 2009 and estimates of certain fourth quarter results. The Company recorded revenue of $15.0 million in the second quarter of 2009, a reduction of 19% as compared to a restated $18.4 million in the second quarter of 2008.
The Company reported basic and diluted net income per share attributable to common stockholders of $0.01 and $0.01, respectively, in the second quarter of 2009, as compared with a restated $0.03 and $0.03, respectively, in the prior year period. Adjusted EBITDA for the second quarter of 2009 was $2.0 million, as compared to a restated $3.3 million for the prior year period.
What They Do: TheStreet.com, Inc. operates as an online financial media company in the United States. It engages audiences on video and digital platforms through TheStreet.com, RealMoney.com, Stockpickr.com, BankingMyWay.com, MainStreet.com and Rate-Watch.com.
PLX Technology (
“Our 24 percent quarterly revenue growth exceeds the industry growth rate and is due to the design-in success that we have had in both the storage and PCI Express switching product categories,” said Ralph Schmitt, president and CEO of PLX. “PLX’s culture is to win and to do it in a profitable manner. The PLX team is dedicated to reducing costs and driving growth. I am proud of their accomplishments in both of these areas in 2009. It was a difficult year but ended very positively for the company, which we believe provides a good launching point for 2010.”
What They Do: PLX Technology is an industry-leading global provider of semiconductor based connectivity solutions primarily targeting the enterprise and consumer markets.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
